Immunic Therapeutics

Also Clin2 progressive MS, Clin2 ulcerative colitis; IMU-856 Clin1 celiac disease; IMU-381 Clin0 GI diseases

Immunic Therapeutics is developing orally administered, small molecule programs for chronic inflammatory and autoimmune diseases. The company's unique science is based on its proprietary platform for the discovery and development of small molecule immunomodulators that target the aryl hydrocarbon receptor (AhR). The AhR is a nuclear receptor that plays a key role in regulating the immune system. Immunic Therapeutics' small molecule AhR modulators are designed to selectively activate the AhR in a way that promotes anti-inflammatory and immunomodulatory effects. This makes them promising candidates for the treatment of a wide range of chronic inflammatory and autoimmune diseases.